• United Kingdom

Accepting PhD Students

1988 …2019
If you made any changes in Pure these will be visible here soon.

Personal profile

Personal Statement

I have two main areas of research interests: the study of leishmaniasis and drug delivery.  My research on leishmaniasis has been involved in understanding the underlying immunological mechansims involved in the control of the disease, the mechananism responible for drug resistance, and development of novel vaccine fomulations to control the infection.  I work on L. donovani, L. major  and L. mexicana  and we have recently started using luciferase-expressing parasites to track the infection.   My drug delivery studies have focused on using non-ionic surfactant vesicles (NIV) to improve drug delivery by the intravenous or pulmonary routes. We are currently involved in commercialising NIV for the pulmonary delivery ('Inhalosomes') through the spin-out comany 'Inhalosome-C Ltd', which is involved in developing a cisplatin product for the treatment of lung cancer.

B10 Fo luc cells imaged using the IVIS® system

Cells were treated with an anticancer drug (columns 3-10) - with the highest concentration in colum 3 and the lowest in column 10.  Column 2 shows the results for the control cells and column 11 shows the results for the negative control. This type of assay is used for screening anticancer compounds.  

Keywords

  • Leishmania
  • drug delivery
  • anticancer treatment
  • vaccines

Fingerprint Dive into the research topics where Katharine Carter is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 28 Similar Profiles
Antimony Sodium Gluconate Medicine & Life Sciences
Leishmania donovani Medicine & Life Sciences
Visceral Leishmaniasis Medicine & Life Sciences
Parasites Medicine & Life Sciences
Surface-Active Agents Medicine & Life Sciences
Infection Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Amphotericin B Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2006 2018

Research Output 1988 2019

Genomic and metabolomic polymorphism among experimentally selected paromomycin-resistant Leishmania donovani strains

Shaw, C. D., Imamura, H., Downing, T., Blackburn, G., Westrop, G. D., Cotton, J. A., Berriman, M., Sanders, M., Rijal, S., Coombs, G. H., Dujardin, J. C. & Carter, K. C., 23 Sep 2019, (Accepted/In press) In : Antimicrobial Agents and Chemotherapy .

Research output: Contribution to journalArticle

Paromomycin
Leishmania donovani
Metabolomics
Parasites
Up-Regulation

IL-4 mediated resistance of BALB/c mice to visceral leishmaniasis is independent of IL-4Rα signaling via T cells

McFarlane, E., Mokgethi, T., Kaye, P. M., Hurdayal, R., Brombacher, F., Alexander, J. & Carter, K. C., 16 Aug 2019, In : Frontiers in Immunology. 10, 13 p., 1957.

Research output: Contribution to journalArticle

Open Access
File
Visceral Leishmaniasis
Leishmania donovani
Interleukin-4
Interleukin-13
T-Lymphocytes

Thesis

An analysis of resistance to miltefosine and paromomycin in leishmania donovani

Author: Shaw, C., 1 Oct 2013

Supervisor: Carter, K. (Supervisor) & Wiese, M. (Supervisor)

Student thesis: Doctoral Thesis

Development of non-ionic surfactant vesicles for inhaled drug delivery

Author: Puig, M., 1 Oct 2015

Supervisor: Carter, K. (Supervisor) & Mullen, A. (Supervisor)

Student thesis: Doctoral Thesis

Activities 2009 2009

  • 1 Key-note speaker and plenary lectures at conferences

4th Worldleish Congress on Leishmaniasis 2009 in Lucknow, India

Katharine Carter (Keynote/plenary speaker)
2009

Activity: Participating in or organising an event typesKey-note speaker and plenary lectures at conferences

Impacts

Economic benefit and competitive advantage from commercial adoption of an innovative non-invasive delivery method for drugs and vaccines

Katharine Carter (Participant), Valerie Ferro (Participant), Alexander Mullen (Participant), James Alexander (Participant)

Impact: Impact - for External PortalEconomic and commerce, Health and welfare - new products, guidelines and services

File